Anteris Technologies Global Corp. a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, has announced it has completed a 90 million USD strategic investment from Medtronic.
The investment closed immediately following Anteris’ underwritten offering of common stock, for a combined 320 million USD in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advances the Company toward global commercialisation of the DurAVR Transcatheter Heart Valve (THV).
Anteris and Medtronic say the companies are aligned around the belief that reshaping the Transcatheter Aortic Valve Replacement (TAVR) market requires advancing clinical science and valve design while maintaining rigorous standards for durability, hemodynamics, and long‑term patient outcomes.
“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator,” said Wayne Paterson, Anteris Vice Chairman and CEO. “The investment is one aspect of a collaboration that may expand into other strategic areas in the future. Anteris has developed a clinically important, evidence-supported product designed to improve the lives of patients with aortic stenosis as we advance toward regulatory approval.”
“The Board is excited to welcome Medtronic to its stockholder community,” said John Seaberg, Chairman of the Anteris Board. “This investment aligns two organisations in their commitment to advancing valve science in a way that is disciplined and focused on long‑term patient benefit.”
Jorie Soskin, Vice President and General Manager of the Structural Heart business in Medtronic’s Cardiovascular portfolio said: “Medtronic is a pioneer in TAVR innovation and evidence. Our investment in differentiated innovation like the DurAVR THV technology, which has the potential to offer improved valve performance in a balloon-expandable platform, is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio.”
The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform the treatment of aortic stenosis. Wells Fargo Securities acted as sole placement agent in connection with the Medtronic investment.
